Randox host Open University students at state-of-the-art Randox Science Park

Randox host Open University students at state-of-the-art Randox Science Park

On Wednesday 15th November, Randox hosted a site visit at its state-of-the-art Randox Science Park in Antrim for Open University (OU) students who are studying a range of subjects including Business, Science, Engineering and Software Development.

Randox is a global leader in healthcare diagnostics, pioneering innovative technologies with major focus in research and development. Their products and services are used in hospitals, clinical, research and molecular laboratories, food testing, forensic toxicology, life sciences, and veterinary laboratories worldwide.

The visit allowed the students the opportunity to experience real life lab experiments in the Research and Development department and the Design Engineering department. They also had the opportunity to tour the different IT departments and see how the operations of a large company work.

Sarah Nicol who is studying for a BSc (Honours) in Computing and IT said:

“It was interesting to hear about the full scope of work taking place within the Randox Science Park and the level of investment confirms that there is a bright future here as an employee.  The training and opportunities available were much wider than I had realised.”

Joanne King who is studying for a BSc (Honours) in Health Sciences said:

“I found the visit interesting and informative.  I enjoyed meeting and hearing from the current Open University students and what they were getting involved with during their placements at Randox.  I certainly found the experience motivating to complete my course as opportunities may be possible with Randox.”

The students were then able to hear from two OU students who are currently on a placement with Randox: Jenny Hope who is studying BSc (Hons) in Health Sciences and Aurelija Gainaite who is studying BSc (Hons) in Natural Sciences. They are both on a one-year placement with Randox and shared with the students the importance of gaining relevant work experience in a chosen field and the potential opportunities it can lead to.

Jolene Carey, Human Resource Officer from Randox said: 

“We were delighted to host The Open University students at Randox – this was a great opportunity for students to gain a valuable insight into the range of different departments within the company and to experience how they work together. We were delighted that OU students Jenny and Aurelija were able to talk directly to their fellow students and explain the benefits of gaining a placement opportunity.  We look forward to continuing to develop our relationship with The Open University.”

 

For further information, please contact our Randox PR team by emailing randoxpr@randox.com or by phoning 028 9442 2413


Randox announces launch of APEX programme 2018 for first year QUB and Ulster University students

Global health diagnostics provider Randox has launched the third year of its innovative APEX Programme. The APEX Programme is a unique career package which offers first year students a paid 8-week summer work experience between first and second year, a paid placement year in their third year of study and, finally, a graduate job if they complete their degree with a 2:1 or above.

There are many different disciplines which are critical for Randox’s global operations, from pioneering research and development scientists to business strategists, savvy marketing teams to top-level engineering departments.

The APEX programme is open to all students currently studying biological sciences but also those studying business, marketing, maths, physics, graphic design, computer science and any form of engineering.

The APEX Programme is like no other in the UK and Randox were pleased to recruit 20 first-year students last year after a high number of applications. The difficulty for students trying to find work experience and a coveted graduate position has been highlighted in recent years. In 2016, official UK government figures reported that one-in-three young graduates were working in low-skilled jobs, being unable to find work which matched their skills. In the same year there was a 2.2% drop in the number of 21 to 30-year-old graduates in skilled worked compared with the year earlier.

The APEX Programme application process is as unique as the programme itself. No CVs or lengthy application forms needed – just submit a 15 second video on Facebook, Twitter or Instagram and 140 character cover note telling us why you are the one for Randox, including hashtags #IAmTheOneQUB or #IAmTheOneUU, depending on your university. It really is that simple! Submit your video from 27th November to 8th December 2017 to be in the running to join the Randox team.

Graduates often face tough competition for jobs in their field of study once they leave university. It’s a well-known cycle for budding young professionals ready to enter their first graduate job – how can I gain the vital experience needed when many roles cite a year or more work experience as an essential requirement?

Linda Magee, Randox Human Resources Manager, says initiatives like the Randox APEX Programme are essential.

“Graduates leave university and enter a tough environment, where expectations are high and competition is fierce. The ones who do best are those who can get the necessary real-life work experience in their area of expertise.

“Randox believes in giving young people a chance to make their mark by taking on real responsibilities right from the start. Undergraduates will work side-by-side with our top teams in science research, manufacturing, engineering, business, marketing and many other disciplines who are working on ground-breaking diagnostic innovations and campaigns which will make an impact globally. 

“As a result, the APEX programme gives our recruits incredible confidence in their abilities. It’s also very important to us that the programme offers paid placements which last for the duration of their degree, so they are able to focus on their studies while working towards a graduate position with a world-leading company after graduation.”

Lee Armstrong, who is studying chemistry at Ulster University, completed his first placement with the APEX Programme in summer 2016 and is now back completing his placement year in the clinical chemistry team. He said:

“I was attracted to the APEX Programme because it was completely different from any other company’s placement – nowhere else do you get a summer placement, a year placement and then a job after graduating if I achieve a 2:1.

“I am currently on my one-year placement, which has allowed me to gain experience with real-life projects. I’m not treated like a student at all – I’m treated like another scientist in the team and I get to work on real projects.

“I would recommend students to apply for the APEX Programme because you gain invaluable experience throughout your degree, there’s the possibility of a job in your field at the end of it – and the application video is much easier than labouring over a CV!”

In 2015, 5% of the world’s population received a diagnosis using a Randox product. It is a world-leading diagnostics company which is developing state-of-the-art facilities at the Science Park in Antrim. It has 1400 employees and operates in 145 countries.

More information about the APEX Programme can be found at http://iamtheone.randox.com 


The Evidence Evolution: The world’s most advanced immunoassay analyser

What sets the Evidence Series apart from its competitors is its flexibility across the range of immunoassay analysers. No other range of analysers has the capability in terms of throughput in comparison to the Evidence Series. With this established, we are delighted to introduce the latest in the Evidence Series range, the Evidence Evolution.

Join the Evolution

We believe that the Evidence Evolution is the world’s most advanced immunoassay analyser. The Evidence Evolution is the most versatile analyser Randox has ever produced. By utilising the same multiplex technology as the other Evidence Series analysers, the Evidence Evolution can process up to 44 results from a single sample, with a maximum throughput of up to 2640 tests per hour. With such a high volume of potential throughput, you may think that reporting time will be compromised, that is simply not the case. The Evidence Evolution can produce the first set of results in less than 36 minutes, with one sample of up to 44 results reported every minute after. The speed of reporting time distinguishes the Evidence Evolution from its competitors, and allows the analyser to further display its capabilities.

Innovation

By utilising patented Biochip Array Technology, the Evidence Evolution offers batch analysis, true random access and STAT testing capabilities. These, combined with retrospective testing, allows the user to build a more in-depth patient profile.

With such swift reporting times, the Evidence Evolution can boast of a true walkaway time of 2 hours, in a laboratory setting, this can be vital. With multiple daily tasks to be completed, time is of the essence, and the Evidence Evolution has been designed to lessen the workload of laboratory staff. By being able to offer a combination of continuous sample and reagent loading, plus automated on-board sample dilution, the Evidence Evolution will have a positive impact in busy laboratories.

Complete Picture

A fast reporting time and high throughput capabilities is just the tip of what the Evidence Evolution can offer. The analyser has the capability to test across multiple matrices, allowing for more flexibility in sampling. It also comes equipped with state of the art intuitive software and advanced precision bio-drive robotics, meaning the Evidence Evolution is an analyser that has been designed and developed to meet the needs of a modern, high throughput laboratory, by a company that has a deep understanding of laboratory needs.

About the Randox Evidence Series

The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.

For more information on the Evidence Evolution, or any of the Evidence Series analysers, please visit http://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.  


We Are Randox | Randox Apprentice Rory McCloskey Wins Gold at National Competition

A Randox Engineer and Northern Regional College apprentice has been recognised as one of the UK’s most talented young tradesmen at an event organised by Worldskills UK.

Rory McCloskey (21) from Antrim was a gold medal winner at the UK National finals in Birmingham. He was competing with over 500 apprentices, exponents of 55 disciplines – as diverse as Aircraft Maintenance to 3D Game Design, Cabinet Making, Plumbing to Beauty Therapy and Cyber Security.

Rory was recognised for his expertise in Computer Numerical Control (CNC) Milling which involves programming, setting and running a modern CNC milling machine to accurately produce a component in a given timeframe.

His journey to the national finals started earlier this year with local College competitions. From here, he progressed through the regional heats and national semi-finals where he finished in the top six in the UK to qualify for the National Worldskills UK 2017 finals which were held in Birmingham from 16 – 18 November.

Rory is a Higher Level Apprentice and works in the engineering department of Randox Laboratories. As a Foundation Degree student at the College’s Ballymena campus, he was trained on state-of-the-art CNC engineering machinery and taught how to program and operate machines such as Mazek, DMG Mori and Doonson, equipment used in modern manufacturing companies throughout Northern Ireland. The College provides education and training in this technology to a wide range of companies, including Ryobi Aluminium Cating, Linamar Montupet, Hutchinson Engineering, Randox Laboratories, McAuley Engineering.

Congratulating Rory on his success, Professor Terri Scott, Chief Executive of Northern Regional College said:

“The award is a great credit to Rory and all the engineering staff at the College and is just reward for all Rory’s hard work and dedication.

“The College has a proud and prestigious tradition of education and training in the field of engineering and I am delighted to see that our provision continues to deliver a consistently high standard.”

Dr Peter FitzGerald, Founder and Managing Director of Randox Laboratories, commented;

“We are incredibly proud of Rory and what he has achieved at the National Worldskills UK 2017 finals. Our apprentices from both the Northern and Southern Regional College are such talented individuals and so we are delighted to be able to offer them the opportunity to carry out ground-breaking research and development with us as they grow and develop in their careers.

“And the apprenticeship scheme is highly valued by the company – just as our students benefit from the time they spend with us, so too do we as a modern and innovative healthcare firm benefit from the fresh perspectives and forward-thinking ideas these students bring to Randox. 

Passionate and hard-working people like Rory make Randox what it is today.  We’re extremely grateful for his contributions to the engineering team here and equally proud of his achievements.  Congratulations Rory.”

Northern Regional College was well represented at the National Worldskills UK finals. Rory was one of seven students from the College’s Ballymena, Coleraine and Newtownabbey campuses to qualify for the final stage of the competition.

The other College finalists were: Dean Boyle, who was rewarded a bronze medal in CNC Milling; Matthew McLaughlin, who was highly commended in Graphic Design; Ryan Moon and Richard Woods (Mechatronics); James McCaughey (IT Software); Patrick McCloskey (Carpentry).

 

For further information about Rory’s award or to find our more about our apprenticeship programme please email randoxpr@randox.com 


RTS – the whistle-blower

  • RTS became a whistle-blower when it uncovered evidence of data manipulation in its laboratory and immediately alerted the authorities
  • Samples themselves were not affected
  • RTS was founded in 2014 and employed staff from the Forensic Science Service and elsewhere in the industry
  • Industry practices were introduced into RTS and were accredited by the UK’s accreditation authority UKAS
  • RTS is supporting the police investigation into the issue and as part of that is managing and financing the retesting process at external laboratories
  • Initial results from re-testing have had no impact on crime cases such as homicide, sexual offences or violence
  • Less than 10% of re-tests resulted in drug driving cases being discontinued
  • A Parliamentary written statement today highlights how the same manipulation may also have occurred at Trimega Laboratories Ltd., which may affect child protection and family court cases.
  • RTS is well-advanced in developing a revolutionary fool-proof testing system based around multiple technological advances by RTS
  • RTS is not connected to Trimega Laboratories. Trimega went into administration in early 2014. After this date, RTS purchased pieces of laboratory equipment from the administrators KPMG and moved into the premises. RTS did not take over Trimega business.

In early 2017, the forensic testing company RTS became a whistle-blower when it exposed evidence of alleged data manipulation. Almost one year on, it remains committed to ensuring the police investigation will succeed in bringing those responsible to justice and protecting the criminal justice system.

When RTS was founded in 2014 it employed staff from the former Forensic Sciences Service and elsewhere in the industry. It discovered, through an internal investigation, evidence of alleged improper practice and brought it to an end by immediately alerting the authorities. A Parliamentary written statement has today highlighted how the same manipulation may have occurred – but crucially went unreported – in a now-defunct laboratory called Trimega Laboratories Ltd, between 2010 and 2014.

The alleged manipulation in RTS involved changing data in testing methods which had been accredited by the UK agency UKAS. The actual samples were not affected which has enabled re-testing, and there is no evidence to suggest that the core purpose of the manipulation was intended to create positive or negative results in any specific tests.

Throughout the ten-month investigation, RTS has worked alongside the police and appropriate authorities to help resolve the issue. It is currently managing the process and covering the costs of re-testing samples at appropriately accredited external laboratories.

Initial re-testing results have had no impact on crime cases such as homicide, sexual offences or violence. Less than 10% of re-tests resulted in drug driving cases being discontinued. The vast majority of these have been because of results consistent with degradation of the original sample resulting in a lower result, or due to insufficient sample being available to enable a re-test. Two road deaths have been referred to the Court of Appeal following the retest.

Two former employees – who had worked at other forensics laboratories before joining RTS – remain on police bail. The investigation is being led by Greater Manchester Police.

RTS Toxicology manager Dr Mark Piper said:

“We have acted as whistle-blower to ensure the integrity of the criminal justice system. We will continue to work with Greater Manchester Police and the appropriate authorities in the investigation. We will do all that we can to ensure this situation is resolved and deeply regret the distress that has been caused.

“We are now well-advanced in developing a fool-proof testing system which would enhance the security of our operations in the future, to provide the necessary level of confidence.”

 

For further information please email randoxpr@randox.com


Diagnosing diabetes with the RX series

Diabetes is a lifelong condition that causes a person’s blood sugar level to become too high.

If you have diabetes, your body is unable to break down glucose into energy. This is because there’s either not enough insulin to move the glucose, or the insulin produced doesn’t work properly [1] which can lead to serious health complications.

The RX series range of analysers have one of the largest test menus available on the market which includes an extensive diabetes testing panel. Tests within the RX series diabetes panel allow for Diagnosis, Monitoring and Risk Assessment of Diabetes.

Adiponectin

An adiponectin test system is a device intended for the quantitative in vitro determination of adiponectin concentration in human serum or plasma.

Adiponectin is a protein hormone, produced and secreted by fat cells (adipocytes), which is normally found in reasonably high concentrations within the blood. Adiponectin regulates the metabolism of lipids and glucose and influences the body’s response to insulin and inflammation.

Adiponectin levels are inversely correlated with abdominal visceral fat (AVF) levels, which have proven to be a strong predictor of several pathologies including metabolic syndrome, type 2 diabetes mellitus (T2DM), cancers and cardiovascular disease (CVD). It is widely recognised that people who are overweight are at a higher risk of developing T2DM, however measure waist circumference and Body Mass Index (BMI) are not enough. As such adiponectin levels are a much more reliable indicator of at-risk patients.

A number of key publications have advocated the testing of adiponectin in clinical settings and concluded that higher adiponectin levels are associated with a lower risk of T2DM across diverse populations.[2]

Fructosamine

A fructosamine test system is a device intended for the quantitative in vitro determination of glycated protein (fructosamine) concentration in human serum or plasma.

Fructosamine is a mid-term indicator of diabetic control as it can provide information on a person’s averge blood glucose levels over the preceding 14-21 days.

 Due to the shorter time span of fructosamine, it is often used to evaluate the effectiveness of medication changes and to monitor the treatment of gestational diabetes.

HbA1c

A Haemoglobin A1c test system is a device intended for the quantitative in vitro determination of Haemoglobin A1c concentration in whole blood.

 In a diabetic patient, where blood glucose levels are abnormally elevated, the level of HbA1c also increases proportionally to the level of glucose in the blood and has been widely accepted as an indicator of the mean daily blood glucose concentration over the preceding 6-8 weeks. It is therefore, a long term indicator of diabetic control.

Read our poster on Randox’s development of a new latex enhanced immunoturbidimetric assay for the rapid direct measurement of glycated haemoglobin (HbA1c) applicable to RX series analysers by clicking here. 

 Diagnosing diabetes with the RX series

The RX series range of clinical chemistry analysers have many benefits when testing patients for diabetes. With analysers ranging from the RX misano semi-automated analyser to the RX modena which can perform up to 1200 tests per hour the RX series analysers offer a suitable platform for your laboratory, ensuring results are received in a time efficient manner. Windows based software and easily recognisable icons ensure that the RX series analysers are easy to use and allows for an enhanced laboratory productivity. Laboratory cost savings can also be achieved with a low water consumption available on each RX series analyser.

Other RX series analyser features include:

Diabetes Test Menu:

Consolidate your testing with a comprehensive diabetes testing panel available on the RX series analysers. A large number of tests can be carried out on one platform, including direct HbA1c testing, providing consolidation opportunities and real cost savings.

Accurate Testing:

High quality results are achieved first time, every time. This saves operator time and avoids unnecessary additional costs of repeat testing and reduces the possibility of patient misdiagnosis.

Unrivalled performance:

Built in inventory management system automatically calculates remaining reagent volume and the number of tests available. Superior performance means minimal downtime and swift reporting of results.

If you would like more information in relation to the RX series testing capabilities please contact us by emailing: theRXseries@randox.com


Randox Health to sponsor Aintree’s Becher Chase

Randox is pleased to announce that Randox Health will be sponsoring the Becher Chase at Aintree Racecourse in a three-year deal.

The £145,000 Randox Health Becher Chase is the centrepiece of Becher Chase Day at Aintree on Saturday, December 9, the only fixture outside of the Randox Health Grand National Festival to feature action over the Grand National fences.

Dr Peter FitzGerald, founder and Managing Director of Randox Health, emphasised Randox Health‘s commitment to both racing and the city of Liverpool.

He said: “We’re delighted to sponsor the Becher Chase, which year-on-year is becoming a more prominent day in the racing calendar for high-calibre horses to compete. With the ongoing work being done by the team at Aintree, that’s no surprise.

“Aintree is a spectacular course and though we will obviously miss the return of One For Arthur, having an open field as we begin the run up to the most exciting race in the whole calendar – the 2018 Randox Health Grand National – will add an unexpected frisson for racing fans.”

As previously announced, Aintree’s Listed Chase over three miles and a furlong on Becher Chase Day, won last year by Many Clouds, has been re-named in honour of the 2015 Grand National winner and upgraded from Listed to Grade 2 level. It will be run as the £50,000 G2 188Bet.co.uk Many Clouds Chase.

John Baker, Managing Director of Aintree Racecourse, added: “We’re thrilled that Randox Health has decided to extend their sponsorship of the Grand National by adding the Becher Chase as well.
 
“Randox is a committed, valued and exciting partner for Aintree and Jockey Club Racecourses and we look forward to working closely with the team at Randox for many years to come.
 
“Becher Chase Day is going from strength to strength and with the quality of horses entered in both the Becher and Sefton Chase in recent years, we’re confident it’s going to be another fantastic day over the iconic Grand National fences at Aintree.”

The G3 Randox Health Becher Chase is a handicap chase over three and a quarter miles of the Grand National course. It serves as an early-season trial for the Randox Health Grand National.

Two winners have gone on to win the Grand National; Amberleigh House and Silver Birch. Earth Summit won the race in 1998 following his Grand National win the previous season.

The second race of the day over the Grand National fences on Becher Chase Day is the £70,000 188bet.co.uk Grand Sefton Handicap Chase over two miles and five furlongs.

In addition to Randox Health’s sponsorship of the Becher Chase and after a successful partnership for Sandown Park Racecourse’s Gents Day this summer, the company will also sponsor the Henry VIII Novices’ Chase at the Esher venue on Saturday, December 9. This is part of the three year agreement with Jockey Club Racecourses to sponsor Becher Chase day.

Entries for the 2017 Randox Health Becher Chase, plus the 188bet Grand Sefton Chase, which also takes place over the Grand National fences, close at noon today Tuesday, November 14 and will be revealed tomorrow, Wednesday, November 15.

Tickets for the 2017 Randox Health Becher Chase raceday are available to purchase at aintree.thejockeyclub.co.uk or by calling 0344 579 3001. Racegoers can also buy tickets directly from the sales office at Aintree Racecourse. Hospitality packages are currently available to purchase, please call 0151 522 2911 for more information.


Sharing our preventive health message this World Diabetes Day

One of the fastest growing health threats of our times is diabetes. Type-2 diabetes is now among the most common long-term health conditions affecting people right across the globe. On World Diabetes Day we want to raise awareness of this particular condition – because it’s possible to spot warning signs and take steps to prevent it.

THE BACKGROUND

Since 1996, the number of people living with diabetes has more than doubled and type-2 diabetes is by far its most prevalent form. Though it is potentially reversible, using more advanced diagnostics, clinicians can diagnose pre-diabetes and enable patients to make lifestyle changes to avoid the condition from developing in the first place.

THE FUTURE

Adiponectin is a biomarker which can powerfully predict the development of pathologies such as Type 2 Diabetes Mellitus (T2DM) and cardiovascular disease (CVD). This biomarker can be tested as an automated biochemistry reagent from Randox.

With the global prevalence of diabetes continually rising in adults over 18 years of age, from 4.7% in 1980 to 8.5% in 2014, adiponectin should be an integral part of every laboratory’s testing panel. Randox Adiponectin will enable physicians and clinicians to accurately evaluate more individuals, with a convenient format for routine clinical use.

When risk is identified via adiponectin measurement, it is essential for individuals to carry out lifestyle modification to lower T2DM risk. This will also help to prevent the development of cardiovascular diseases and metabolic syndrome. This indicates that Randox automated adiponectin should be a routinely run test across the world.

OUR CASE STUDY – SIR AP MCCOY

Earlier this year Sir AP McCoy came to Randox Health. After a career dedicated to becoming the world’s most successful jockey, he was never going to leave the next stage of his life to chance. It was lucky he did: our advanced test for adiponectin was within the panel of tests run and  was able to identify that AP was pre-diabetic.

Don’t leave your health to chance. 70% of cases of type-2 diabetes are preventable by adopting a number of lifestyle changes, so take action today.

For further information phone the Randox PR Team on 028 9442 2413, or email randoxpr@randox.com 


Randox showcases future-proofing diagnostic technology at MEDICA 2017

Randox Laboratories, the world-leading medical diagnostics manufacturer, is showcasing advancements in laboratory technology at the 2017 MEDICA – World Conference for Medicine conference, being held November 13-16 in Dusseldorf, Germany.

Unveiling its state-of-the-art interactive exhibition stand, Randox will host a series of demonstrations of its innovative analysers including the Evidence Evolution and Rx modena, and a number of exciting advances in laboratory medicine, involving  increasing the test menu available to clinicians and improving the connectivity of laboratories across the world to improve overall quality.

“Through our advancements in laboratory innovation, we’re driving an industry-wide evolution” said Randox CEO, Dr Peter FitzGerald.

“Our products are leading the way in innovation and enabling laboratories to transform the way they operate. We will be hosting demonstrations of a wide range of our fully-automated analysers, which are packed with cutting-edge technology and intuitive software. The goal is to provide future-proof diagnostic technology that will create the most efficient and effective laboratories.”

Paving the way is Randox’s patented Biochip Array Technology (BAT). This multi-analyte testing platform is the product of a £250 million research and development project. The ceramic tile measuring 9×9 mm can currently run up to 49 assays simultaneously,100 assays in the near future.   This innovation allows the simultaneous quantitative or qualitative detection from a wide range of analytes from a single sample. It is suitable for use in a wide range of laboratories including clinical, research, hospital, veterinary and forensic and clinical toxicology.

To enhance the benefits of BAT, Randox introduced the Evidence Evolution to its stable of immunoassay analyser platforms. The Evidence Evolution is the world’s first fully automated random-access biochip testing platform, capable of delivering 2640 results in one hour, with the first delivered in just 37 minutes.

Joining the Evolution in Hall 3 stand A08 is the RX modena. This highly reliable, precise, fully automated clinical chemistry analyser can run 1200 tests per hour including ISE. When combined with its unrivalled RX series test menu, it offers a winning combination for all large, multi-disciplinary laboratories.

“We develop more new tests than any other diagnostics manufacturer, and one of the products that we’re showcasing at this year’s MEDICA is Adiponectin,” added Susan Hammond, Global Sales Manager at Randox.

“This novel biomarker is a powerful new weapon in the fight against some of the biggest health issues faced throughout the world including diabetes, cancers and cardiovascular disease. As it’s World Diabetes Day on Tuesday 14th November, it’s a great opportunity to draw attention to this array which labs can run as part of their routine testing panel.”

MEDICA attendees will also be among the first to experience the advancements delivered by the latest update for Randox’s Acusera 24.7. This online interlaboratory data management and peer reporting package is now smarter, faster and more powerful than ever before.

Acusera 24.7 is designed to help laboratories efficiently review QC data from all their lab instruments on one central platform, thereby allowing quick and easy identification of QC failures and emerging trends. Unique access to peer group data updated instantly in real-time from our global network of laboratory participants will speed up troubleshooting and help pinpoint the root cause of any QC failures by easily identifying if an issue is isolated or widespread.

 

The Randox team will be on hand throughout MEDICA 2017 at stand #3A08. To make an appointment in advance, contact them through the Randox MEDICA webpage.

Click here for more information on Randox, or to get in touch, phone the Randox PR Team on 028 9442 2413, or email randoxpr@randox.com 


From Columbia to the UK: The trail that’s fuelling the worldwide cocaine epidemic

With the demand for cocaine in the UK rocketing, Top British Chef Gordon Ramsay has recently travelled to Columbia to the source of the problem, to learn more about this growing epidemic.

Having spent time with local farmers who own cocaine plants that resemble vineyards, and visiting Honduras, one of the most dangerous countries and known as the world’s warehouse of cocaine, he emphasized the urgent need to combat the drugs industry that is consuming this country.

Highlighted throughout the two-part series was the amount of cocaine that is being trafficked to the shores of the UK each year. Speaking with the metropolitan police who tackle up to 200 drug gangs in London alone, it was estimated that up to 300 tons of cocaine, with a street value of £10 billion, is being brought in to the country through a web of secretive routes used by drug traffickers.

Gordon commented that not only is cocaine a growing global problem, but it is one that is prevalent within the culinary world, including his own restaurants where he has been asked to dust the drug on top of soufflés as icing sugar, and found traces of this deadly drug in both his staff and customer toilets.

With the cocaine problem showing no signs of slowing down, Randox Toxicology are constantly working to develop the newest drug tests to meet the demands of the ever-growing drug market. The Evidence MultiSTAT was developed for use in non-laboratory settings such as workplaces, police stations and low throughput laboratories and to provide highly accurate qualitative as quickly as possible.

This revolutionary analyser enables on-site simultaneous detection of up to 21 classical, prescription and synthetic drugs from a single patient sample, reducing the burden on current systems, the risk of adulteration and helping the fight against the cartels who control the cocaine trade in South America.

For more information on our Evidence Analysers or any of our drug panels email info@randoxtoxicology.com


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro Ćŗltimo seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, ktĆ³re są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktĆ³w,akutalizacji obecnych, trendĆ³w rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, ktĆ³re są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktĆ³w,akutalizacji obecnych, trendĆ³w rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, ktĆ³re są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktĆ³w,akutalizacji obecnych, trendĆ³w rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
    Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, ktĆ³re są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktĆ³w,akutalizacji obecnych, trendĆ³w rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
×
ź·€ķ•˜ģ˜ ė¬øģ˜ ģ‚¬ķ•­ ģ œģ¶œ
    Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
ź·€ķ•˜ģ˜ ė¬øģ˜ ģ‚¬ķ•­ ģ œģ¶œ
×
ź·€ķ•˜ģ˜ ė¬øģ˜ ģ‚¬ķ•­ ģ œģ¶œ
×
ź·€ķ•˜ģ˜ ė¬øģ˜ ģ‚¬ķ•­ ģ œģ¶œ
×
Downloads
×
Contact

<p>

    Randox Clinical Chemistry Products Join the Randox Laboratories Mailing List * I would like to receive emails with new product releases and updates from Randox Laboratories, market trends, and more. I do not want to receive email marketing from Randox. Signing up to our mailing list is quick and easy. We do not want to send you any spam or junk emails, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promises never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
</p>

×
Enquire Now - Coronavirus Testing
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details safe and secure. Read more in our Privacy Policy.
×